C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 213/78 (2006.01) A61K 31/44 (2006.01) A61K 31/455 (2006.01) A61P 3/04 (2006.01) A61P 25/00 (2006.01) C07D 213/60 (2006.01) C07D 401/12 (2006.01)
Patent
CA 2479744
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
Ces nouveaux composés représentés par la formule structurelle (I), qui sont des antagonistes et/ou des agonistes inverses du récepteur des cannobinoïdes-1 (CB1), conviennent pour le traitement, la prévention et la suppression des affections où intervient la médiation du récepteur des CB1. Les composés de l'invention conviennent comme médicaments agissant centralement dans le traitement de la psychose, du défaut de mémoire, de troubles cognitifs, de la migraine, de la neuropathie, de troubles neuro-inflammatoires comprenant notamment la sclérose en plaque, le syndrome de Guillain-Barre et les séquelles inflammatoires de l'encéphalite virale, d'accidents cérébrovasculaires et de traumatismes crâniens, de troubles de l'anxiété, du stress, de l'épilepsie, de la maladie de Parkinson, de troubles moteurs, et de la schizophrénie. Ces composés conviennent également pour le traitement de troubles toxicomaniaques, le traitement de l'obésité ou de troubles de l'alimentation, ainsi que le traitement de l'asthme, la constipation, la pseudo-obstruction intestinale chronique, et la cirrhose.
Debenham John S.
Finke Paul E.
Meurer Laura C.
Toupence Richard B.
Walsh Thomas F.
Merck & Co. Inc.
Merck Sharp & Dohme Corp.
Ogilvy Renault Llp/s.e.n.c.r.l.,s.r.l.
LandOfFree
Substituted 2,3-diphenyl pyridines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted 2,3-diphenyl pyridines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 2,3-diphenyl pyridines will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1590593